Drugs / Ficonalkib
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05257512 | Apr 2020 → Apr 2024 | non-small cell lung carcinoma | Shouyao Holdings (Beijing) Co. LTD | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ficonalkib | “Ficonalkib (SY-3505) in Advanced ALK-Positive NSCLC: A Multicenter, Open-Label, Single-Arm, Phase 1/2 Study.” PMID 38295954 ↗ Jan 2024 |
| Known as | SY-3505 | “Ficonalkib (SY-3505) in Advanced ALK-Positive NSCLC: A Multicenter, Open-Label, Single-Arm, Phase 1/2 Study.” PMID 38295954 ↗ Jan 2024 |
| Action | Inhibit | “a third-generation (3rd-gen) ALK TKI” PMID 38295954 ↗ Jan 2024 |
| Modality | Small molecule | — CHEMBL5314461 ↗ |
| Target | ALK | “a third-generation (3rd-gen) ALK TKI” PMID 38295954 ↗ Jan 2024 |